Challenges to pharma charging premium prices for branded drugs are not new. Think of President Biden’s attempts to drive down prices with the Inflation Reduction Act. Or the UK’s strategy of capping the price the NHS pays for branded medicines with its VPAG rebate scheme. But President Trump’s “most favoured nation” policy – which attempts […]
The catastrophic fall from grace of the genetic testing app 23 and Me is a salutary lesson for all companies that espouse the use of “big data” in healthcare. Once a leading digital health tech firm, worth $6 billion as recently as 2021, the company is now on the verge of being taken private at […]
OZEMPIC, Wegovy, Mounjaro, Zepbound: they’ve quickly become part of our vocabulary. In just a few years, powerful GLP-1 drugs, first introduced to control Type 2 diabetes but now much better known for their ability to help people rapidly lose weight, have become indispensable weapons in the Battle of the Bulge. In the UK alone, some […]
We hope you are enjoying Optimum’s weekly newsletter – subscribe on LinkedIn today so you never miss an edition. Our clients Loqus23 Therapeutics and Ona Therapeutics continued the stream of good news for February with key leadership appointments. LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors LoQus23 Therapeutics Ltd, […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
